8/6/2020 4:27:46 PM
Geron Q2 Loss/Shr $0.06 Vs Loss $$0.08 Last Year
7/16/2020 8:33:21 AM
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
7/1/2020 8:33:57 AM
Geron Receives Positive Opinion From EMA' COMP For Orphan Drug Designation For Imetelstat
5/22/2020 7:20:15 AM
Geron Prices Public Offering Of Common Stock And Warrants
4/16/2020 8:35:29 AM
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/2/2020 8:16:01 AM
Geron Expects Spending In 2020 To Be Lower Than Prior View Of $70- $75 Mln
2/20/2020 8:04:41 AM
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/23/2020 11:26:56 PM
Johnson Fistel Says That It Has Filed Class Action Against Geron
1/16/2020 8:03:27 AM
Geron Reports Inducement Grants Under Nasdaq Listing Rule
12/19/2019 8:06:04 AM
Geron Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/3/2019 8:04:22 AM
Geron Appoints Anil Kapur As EVP, Corporate Strategy And Chief Commercial Officer
8/8/2019 8:25:40 AM
Geron Begins Phase 3 Portion Of IMerge To Evaluate Imetelstat